Tag Archives: risk of heart disease

Men can inherit heart disease

Men can inherit heart disease from their father say scientists who have tracked the condition to the Y chromosome that dads pass to sons.

By studying the DNA of over 3,000 men they found a particular version of the sex chromosome increases the risk of coronary artery disease by 50%.

As many as one in five British men carry this version of Y.

And the risk it confers is in addition to other heart risk factors like cholesterol, The Lancet reports.

Experts already know that men develop heart disease a decade earlier than women, on average. By the age of 40, the lifetime risk of heart disease is one in two for men and one in three for women.

Lifestyle factors like smoking and blood pressure are important contributors. This latest work suggests the male Y chromosome can also play a role in coronary artery disease – a common form of heart disease that kills thousands each year in the UK.

Dr Maciej Tomaszewski, from the University of Leicester, and colleagues studied 3,233 biologically unrelated British men who were already enrolled in other medical studies investigating heart disease risk.

When they carried out genetic tests on the men they found that 90% possessed one of two common versions of Y chromosome – named haplogroup I and haplogroup R1b1b2.

And the risk of coronary artery disease among the men carrying the haplogroup I version was 50% higher than in other men.

The human heart

The human heart

The scientists say they now need to pinpoint precisely which genes on the Y chromosome are responsible.

But they believe they already know how they exert their effect – by upsetting a man’s immune system.

Dr Maciej Tomaszewski, a clinical senior lecturer at the University’s Department of Cardiovascular Sciences, said: “We are very excited about these findings as they put the Y chromosome on the map of genetic susceptibility to coronary artery disease.


“Doctors usually associated the Y chromosome with maleness and fertility but this shows it is also implicated in heart disease.”

He said, ultimately, the discovery could lead to new ways to treat and prevent heart disease in men, as well as a genetic test to spot those greatest risk.

In the meantime, he said men should focus on risk factors that they already have the power to modify themselves, such as getting enough exercise and eating a healthy diet to keep their blood pressure and cholesterol down.

Dr Hélène Wilson of the British Heart Foundation, which part-funded the work, said: “Coronary heart disease is the cause of heart attacks, which claim the lives of around 50,000 UK men every year.

“Lifestyle choices such as poor diet and smoking are major causes, but inherited factors carried in DNA are also part of the picture. The next step is to identify specifically which genes are responsible and how they might increase heart attack risk.”

New diabetes drug approved

Amylin Pharmaceuticals Inc won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company’s most promising product.

After two delays, the Food and Drug Administration approved once-weekly injectable Bydureon for treating adults with Type 2 diabetes, which is linked to poor diet and lack of exercise. Bydureon is a longer-acting form of Amylin’s older Byetta treatment.

Amylin shares jumped 16.6 percent to $14.16 in after hours trading on Nasdaq. The shares of partner Alkermes Plc, which provided some technology for the medicine, rose 4.7 percent to $20.

More than 300 million people worldwide suffer from diabetes, including nearly 26 million Americans. They run a high risk of heart disease, stroke, kidney failure, blindness and limb loss.

Bydureon is seen as Amylin’s most important new drug, and critical to its future earnings growth, with analysts estimating peak sales of close to $1 billion.

But after repeated delays in gaining approval in the United States, the medicine faces a daunting competitive landscape.

Novo Nordisk’s Victoza, another injectable diabetes medicine, has had almost two extra years to gain traction with patients and doctors. The delays have also given time for potential rival treatments from GlaxoSmithKline Plc and Sanofi SA to catch up.

The FDA had rejected Bydureon twice before, most recently in October 2010, asking for more data on potential side effects to the heart. A trial of Bydureon in July found no link between the drug and changes in heart rhythms, the company said.

Diabetes

Diabetes

However, as a condition of approval, the FDA said on Friday Amylin must conduct another long-term clinical trial by 2018 to study heart-related side effects from Bydureon.

Taken once a week, Bydureon has been viewed as crucial to sustaining the franchise started by the twice-daily Byetta.

Investors are closely watching whether Amylin will be able to pull off a successful launch without the help of long-time partner Eli Lilly & Co after the two companies broke off their diabetes partnership in November. Alkermes would also get royalties from the sales of Bydureon.


Amylin will price its new drug at $323.44 for four weeks of therapy and make it available in U.S. pharmacies starting in February.

The company also plans to hire 650 sales specialists who will promote Bydureon and Byetta to doctors, and start working by March, the company said in a conference call with investors.

Mark Schoenebaum, an analyst at ISI group, said Bydureon’s price was equivalent to about $4,200 a year, compared with about $3,400 to $5,000 for Novo Nordisk’s Victoza, depending on the dose.

Victoza, which is injected daily, proved superior to Bydureon in controlling blood sugar levels, trial results published last March showed. But Bydureon may get a boost because of its more convenient dosing.

Analysts at Deutsche Bank expect peak Bydureon sales of $1.5 billion, above market forecasts of $940 million by 2016, because of its convenience compared with Victoza.

Bydureon, Byetta and Victoza belong to the new GLP-1 class of therapies that stimulate insulin production when blood sugar levels become too high. They can also prompt weight loss, a benefit because obesity is a leading cause of diabetes.

European regulators approved Bydureon as a treatment for Type 2 diabetes in April 2011.